Prof Tran graduated from medical school at Guy's and St Thomas' Hospitals in 1999, before completing her basic surgical training in London.

She was awarded a Medical Research Council funded clinical training fellowship for her PhD at Imperial College and completed specialist urology training while continuing academic research as a National Institute for Health and Care Research (NIHR) clinical lecturer at Cambridge University Hospitals.

Prof Tran was appointed honorary consultant urological surgeon at the Royal Free Hospital and senior lecturer in kidney Cancer at University College London (UCL) in 2015.

She has led the development of the kidney cancer research programme, which now has seven PhD students, a dedicated kidney cancer research laboratory in the Pears Building and six NIHR portfolio clinical trials. She became professor of urology at UCL in 2022.

Her surgical interest is in minimally invasive (laparoscopic and robot-assisted) and complex open kidney surgery. Both her clinical and academic research interests are focused on improving the understanding, diagnosis and treatment outcomes in early-stage kidney cancer.

She was the first vice dean for equality, diversity and inclusion for UCL’s Faculty of Medical Science, and has served on the specialist advisory committee in Urology and the Joint Committee on Surgical Training.

GMC number


• Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Marco Sciacovelli1, Emanuel Gonçalves, Isaac Timothy Johnson, Vinny Zecchini, Anna Sofia Costa, Edoardo Gaude, Alizee Vercauteren Drubbel, Maxine Tran, Vinothini Rajeeve, Pedro Cutillas, Anne Warren, Vincent Gnanapragasam, Eamonn Richard Maher, Patrick Henry Maxwell, Julio Saez-Rodriguez & Christian Frezza.Nature (Accepted, August 2016)
• The small renal mass. Where is the wisdom we have lost in knowledge? Where is the knowledge we have lost in information? Aitchison M, Tran M. BJU Int. 2016 Jun;117(6):851-2. doi: 10.1111/bju.13373.
• Sign of the times: be careful what you say in the operating room. Tran M, Tadtayev S, Palmer T, Evans A, Mumtaz F. Lancet. 2016 Feb 6;387(10018):536. doi: 10.1016/S0140-6736(16)00224-5.
• A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Simoes-Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer LG. J Pathol. 2015 Aug;236(4):517-30. doi: 10.1002/path.4547.
• Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Kovac M, Navas C, Horswell S, Salm M, Bardella C, Rowan A, Stares M, Castro-Giner F, Fisher R, de Bruin EC, Kovacova M, Gorman M, Makino S, Williams J, Jaeger E, Jones A, Howarth K, Larkin J, Pickering L, Gore M, Nicol DL, Hazell S, Stamp G, O'Brien T, Challacombe B, Matthews N, Phillimore B, Begum S, Rabinowitz A, Varela I, Chandra A, Horsfield C, Polson A, Tran M, Bhatt R, Terracciano L, Eppenberger-Castori S, Protheroe A, Maher E, El Bahrawy M, Fleming S, Ratcliffe P, Heinimann K, Swanton C, Tomlinson I. Nat Commun. 2015 Mar 19;6:6336. doi: 10.1038/ncomms7336.
• PROMs in male incontinence surgery. MGB Tran, J Yip, K Uveili, S Biers and N Thiruchelvam. Annals of the Royal College of Surgeons of England. Oct 2014 pp. 521-525(5)
• Renal tubular HIF-2? expression requires VHL inactivation and causes fibrosis and cysts. Schietke RE, Hackenbeck T, Tran M, Günther R, Klanke B, Warnecke CL, Knaup KX, Shukla D, Rosenberger C, Koesters R, Bachmann S, Betz P, Schley G, Schödel J, Willam C, Winkler T, Amann K, Eckardt KU, Maxwell P, Wiesener MS. PLoS One. 2012;7(1):e31034. Epub 2012 Jan 27.
• Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease. Shively SB, Falke EA, Li J, Tran MG, Thompson ER, Maxwell PH, Roessler E, Oldfield EH, Lonser RR, Vortmeyer AO. Mod Pathol. 2011 Aug;24(8):1023-30. doi: 10.1038/modpathol.2011.61. Epub 2011 Apr 15.
• Progression of epididymal maldevelopment into harmatoma-like neoplasia in vhl disease. Mehta GU, Shively S, Duong H, Tran MGB, Moncrief TJ, Smith JH, Li Edwards NA, Lonser RR, Zhuang Z, Merrill MJ, Raffeld M, Maxwell PH, Oldfield EH and Vortmeyer AO. Neoplasia 2008 Oct, vol 10, no. 10 p1146-1153
• Inhibition of HIF hydroxylases protects against renal ischemia-reperfusion injury. Hill P, Shukla D, Tran MGB, Aragones J, Cook HT, Carmeliet P and Maxwell PH. Journal of the American Society of Nephrology 2008 19: 39-46
• New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. Massie CR, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MGB, Neal DE and Mills IG. EMBO reports 2007 vol8, no 9 871-878
• Evolution of VHL tumorigenesis in nerve root tissue. Vortmeyer AO, Tran MGB, Zeng W, Glasker S, Riley C, Tsokos M, Ikeji. B, Merrill MJ, Raffeld M, Zhuang Z, Lonser RR, Maxwell PH, Oldfield EH. Journal of Pathology 2006 Sep 18; [Epub ahead of print]
• Epididymal cystadenomas and epithelial tumorlets: Effects of VHL deficiency on human epididymis. Glasker S, Tran MGB, Shively S, Ikejiri B, Lonser RR, Maxwell PH, Zhuang Z, Oldfield EH, Vortmeyer AO. Journal of Pathology 2006 Sep;210(1):32-41
• Matrix protein “low expression” regions in venular basement membranes act as exit points for neutrophils migrating through venular walls. Wang S, Voisin M, Dangerfield J, Tran MGB, Maxwell PH, Sorokin L, Noursshargh S. Journal of Exp Medicine 2006 Jun 12;203(6):1519-32
• Formation of Primary Cilia in the kidney epithelium is regulated by the VHL tumor suppressor protein. Esteban MA, Harten SK, Giles RH, Tran MGB, Maxwell PH. Journal of the American Society of Nephrology 2006 Jul;17(7):1801-6
• Regulation of E-cadherin expression by the VHL tumour suppressor protein via hypoxia-inducible factor. Tran MGB*, Esteban MA*, Hill P, Harten SK, Chandra A, Raval R, O’Brien TS, Maxwell PH. (* equal contribution) Cancer Res. 2006 Apr 1;66(7):3567-75
• Tumour cell plasticity in Ewing Sarcoma; an alternative circulatory system stimulated by hypoxia. van der Schaft DWJ, Hillen F, Pauwels P, Kirschmann D, Castermans K, oude Egbrink MGA, Tran MGB, Sciot R, Hauben E, Hogendoom CW, Delattre O, Maxwell PH, Hendrix MJC, Griffeon AW. Cancer Res. 2005; 65(24):11520-8.
• Effects of VHL deficiency on Endolymphatic Duct and Sac. Glasker S, Lonser RR, Tran MGB, Ikejiri B, Butman JA, Zeng W, Maxwell PH, Zhuang Z, Oldfield EH, Vortmeyer AO. Cancer Res. 2005; 65(23):10847-53
• Contrasting properties of HIF-1alpha and HIF-2alpha in VHL-associated renal cell carcinoma. Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Molecular Cell Biology, 2005 25 (13), 5675-5686
• Jellyuria – a symptom of neoplastic urachal disease. Tran MGB, Cahill D, Chandra A, O’Donnell PJ, O’Brien TS. BJU International 2002 90 (9cr), 973

Prof Tran's research focuses on using novel clinical and translational approaches to advance the understanding of the underlying biology and transform the outcomes for patients diagnosed with early-stage kidney tumours, the largest growing population of kidney cancer patients.